Target intelligence / Profile preview

Crossover junction endonuclease MUS81-Essential meiotic structure-specific endonuclease 1 complex (MUS81-EME1)

Target
MUS81-EME1
Molecular classification
Enzyme, Endonuclease, DNA repair protein complex, Structure-specific endonuclease
01

Overview

The Crossover junction endonuclease MUS81-Essential meiotic structure-specific endonuclease 1 (MUS81-EME1) complex is a heterodimeric structure-specific endonuclease that plays a pivotal role in DNA repair and the maintenance of genome stability (UniProt: Q96NY9, Q8NBL1). It is primarily responsible for the resolution of branched DNA intermediates, such as Holliday junctions and stalled replication forks, particularly during the late G2 and M phases of the cell cycle (PubMed: 21741376). By cleaving these structures, the complex facilitates the completion of homologous recombination and ensures proper chromosome segregation. In clinical oncology, MUS81-EME1 is a significant target for synthetic lethality strategies, especially in tumors with deficiencies in other DNA repair pathways like BRCA1/2 or ATM (PubMed: 30635538). Inhibition of the complex in these susceptible backgrounds leads to an accumulation of toxic DNA intermediates, resulting in mitotic catastrophe and apoptosis. Current drug discovery efforts are focused on identifying potent small-molecule inhibitors to exploit these vulnerabilities in various cancers, including breast and ovarian malignancies (PubMed: 32884058).

Other names
MUS81-MMS4 complexMUS81-EME1 endonucleaseStructure-specific endonuclease MUS81-EME1
02

Mechanism of action

Inhibition of the endonuclease activity of the MUS81-EME1 complex to prevent the resolution of DNA recombination intermediates, leading to synthetic lethality in DNA-repair-deficient cancer cells (PubMed: 30635538).

03

Biological functions

DNA repairHomologous recombinationResolution of Holliday junctionsReplication fork recoveryMaintenance of genomic stability
04

Disease associations

CancerBreast cancerOvarian cancerProstate cancer
05

Safety considerations

Potential for off-target genomic instabilityHematological toxicityRisk of secondary malignanciesToxicity to normal proliferating cells
06

Interacting drugs

Experimental MUS81 inhibitors
07

Biomarkers

BRCA1 mutationBRCA2 mutationATM deficiencyPTEN deficiencyHigh replication stress

Beyond the preview

Go deeper on Crossover junction endonuclease MUS81-Essential meiotic structure-specific endonuclease 1 complex (MUS81-EME1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crossover junction endonuclease MUS81-Essential meiotic structure-specific endonuclease 1 complex (MUS81-EME1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call